Aligos Therapeutics, Inc.
ALGS
$4.68
$0.112.41%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -131.21M | -76.95M | -75.74M | -99.59M | -87.68M |
| Total Depreciation and Amortization | 2.62M | 2.73M | 2.74M | 2.90M | 3.07M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 52.80M | -5.91M | -4.36M | 28.68M | 15.14M |
| Change in Net Operating Assets | -4.96M | -4.86M | -7.88M | -11.35M | -9.53M |
| Cash from Operations | -80.74M | -85.00M | -85.23M | -79.36M | -79.00M |
| Capital Expenditure | -130.00K | -109.00K | -95.00K | -81.00K | -19.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -7.00K | 0.00 | 0.00 |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -18.15M | -38.15M | -48.56M | -63.57M | 45.00M |
| Cash from Investing | -18.28M | -38.26M | -48.67M | -63.65M | 44.98M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -83.00K | -44.00K | -60.00K | -91.00K | -96.00K |
| Issuance of Common Stock | 438.00K | 17.83M | 17.83M | 17.99M | 18.02M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 70.41M | 70.41M | 70.41M | 70.41M |
| Cash from Financing | 355.00K | 88.19M | 88.18M | 88.31M | 88.33M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -98.67M | -35.06M | -45.72M | -54.70M | 54.31M |